Skip to main content
. 2012 Oct 16;107(10):1714–1721. doi: 10.1038/bjc.2012.455

Figure 1.

Figure 1

Bicalutamide (BCA) treatment increases RUNX2 expression in LNCaP tumours in vivo; hypoxia increases RUNX2 expression in LNCaP cells in vitro. (A) Representative images of RUNX2 staining in LNCaP tumours. Magnification × 400. (B) Percentage of LNCaP cells staining positively for RUNX2. Results shown are mean±s.e. of five regions of interest for three slides for each of the three independent tumours. (C) RUNX2 mRNA fold change in tumours measured using RT–Q-PCR. Results shown are mean±s.e. of three independent tumours. (D) RUNX2 mRNA fold change in LNCaP cells treated with BCA in vitro (4.6 μℳ). Results shown are mean±s.e. of four independent experiments. (E) RUNX2 mRNA expression in oxia and acute (0.1% O2 for 2 h) and chronic (0.1% O2 for 24 h) hypoxia. Results shown are mean±s.e. of three independent experiments. (F) RUNX2 mRNA expression under oxic or hypoxic (0.1% O2) conditions after exposure to actinomycin D (5 μg ml−1). Results shown are mean±s.e. of three independent experiments. *P⩽0.05, **P⩽0.01 and ***P⩽0.001 (two-way ANOVA).